Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Day

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
American Journal of Ophthalmology|August 6, 2000
Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressureW C Stewart, E D Sharpe, T S Harbin, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 2, 2001
Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertensionW C Stewart, D G Day, J A Stewart, et al.
Eye (London, England)|April 20, 2004
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertensionE D Sharpe, C J Henry, T K Mundorf, et al.
American Journal of Ophthalmology|October 6, 2000
Factors associated with long-term progression or stability in primary open-angle glaucomaW C Stewart, A E Kolker, E D Sharpe, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 29, 2000
Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertensionW C Stewart, E D Sharpe, D G Day, et al.
European Journal of Ophthalmology|October 14, 2008
Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucomaW C Stewart, A E Kolker, E D Sharpe, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
American Journal of Ophthalmology|August 6, 2000
Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressureW C Stewart, E D Sharpe, T S Harbin, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 2, 2001
Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertensionW C Stewart, D G Day, J A Stewart, et al.
Eye (London, England)|April 20, 2004
Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertensionE D Sharpe, C J Henry, T K Mundorf, et al.
American Journal of Ophthalmology|October 6, 2000
Factors associated with long-term progression or stability in primary open-angle glaucomaW C Stewart, A E Kolker, E D Sharpe, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|June 29, 2000
Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertensionW C Stewart, E D Sharpe, D G Day, et al.
European Journal of Ophthalmology|October 14, 2008
Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucomaW C Stewart, A E Kolker, E D Sharpe, et al.
Pageof 3